Compare · GLP-1 agonist
CagriSema vs Retatrutide
Both are glp-1 agonist compounds. Here's how they line up on the evidence — graded the same way.
| CagriSema | Retatrutide | |
|---|---|---|
| Evidence | Strong human | Preliminary human |
| Class | GLP-1 agonist | GLP-1 agonist |
| Summary | An investigational once-weekly fixed combination of cagrilintide (an amylin analog) plus semaglutide (a GLP-1 drug) with large peer-reviewed Phase 3 weight-loss data, but no approval yet and a failed head-to-head against tirzepatide. | An investigational triple-hormone agonist with striking weight-loss data in trials, but not yet FDA-approved and with no peer-reviewed Phase 3 results. |
| Full profile → | Full profile → |
CagriSema
CagriSema is one of the most heavily studied combination products in the obesity-drug pipeline, and also a useful case study in why "strong trial data" and "proven, approved, and better than the alternatives" are not the same thing. It is a once-weekly injectable that fixes two peptides into a…
Retatrutide
Retatrutide (Lilly code LY3437943) is an investigational injectable drug for obesity and type 2 diabetes. It has produced some of the largest weight-loss figures seen in trials so far, but as of June 2026 it is not approved anywhere and its pivotal Phase 3 data have not yet been peer-reviewed.